Galapagos (GLPG) Receives a Hold From Morgan Stanley
Morgan Stanley Sticks to Its Hold Rating for Galapagos (GLPG)
Kepler Capital Sticks to Their Hold Rating for Galapagos (GLPG)
Galapagos Analyst Ratings
Galapagos Analyst Ratings
Galapagos Analyst Ratings
Galapagos Analyst Ratings
Galapagos (GLPG) Gets a Hold From RBC Capital
TD Cowen Sticks to Their Buy Rating for Galapagos (GLPG)
Galapagos Analyst Ratings
JPMorgan Cuts Galapagos Price Target to $37 From $45, Maintains Neutral Rating
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Andlauer Healthcare Group (OtherANDHF) and MoonLake Immunotherapeutics (MLTX)
TD Cowen Keeps Their Buy Rating on Galapagos (GLPG)
Analysts Conflicted on These Healthcare Names: Galapagos (GLPG) and Immunocore Holdings (IMCR)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP) and Galapagos (GLPG)
Morgan Stanley Maintains Equal-Weight on Galapagos, Lowers Price Target to $40
Galapagos Analyst Ratings
Morgan Stanley Reaffirms Their Hold Rating on Galapagos (GLPG)
RBC Cuts Price Target on Galapagos to $38 From $41, Keeps Sector Perform Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Select Medical (SEM), Travere Therapeutics (TVTX) and Galapagos (GLPG)